US 2022/0033911 A1Published application

Method for determining prognosis of endometrial cancer

AssigneesKeio University, Sekisui Medical Co., Ltd.

InventorsYae KANAI, Eri ARAI, Daisuke AOKI, Nobuyuki SUSUMU, Wataru YAMAGAMI, Takeshi MAKABE

Life of this patent

Estimating the term…

Loading patent…

Abstract

Provided are a method for determining prognosis of endometrial cancer, a method for determining endometrial cancer patient compatible to preservation therapy, and a method for determining risk of endometrial cancer. The methods comprise detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell, endometrial cancer cell or tissue containing the cell. Prognosis of endometrial cancer, compatibility to preservation therapy, or risk of endometrial cancer of a subject is determined on the basis of the detected DNA methylation level.

Claims22

Dependent claims

A method for detecting a cell or tissue derived from an endometrial cancer patient with poor prognosis, the method comprising:

detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cancer cell or tissue containing the cell;
and
detecting a cell or tissue derived from the endometrial cancer patient with poor prognosis, on the basis of the detected DNA methylation level,
wherein the target CpG site is at least one CpG site selected from the group consisting of CpG sites located at or near the chromosomal positions listed in Table A.
TABLE A
CpG site
Chromosome
Chromosomal
Chromosome
Chromosomal
Chromosome
Chromosomal
No.
position
No.
position
No.
position
10
106400259
13
112759355
10
18583838
8
56852290
7
35301188
12
61961255
14
60973823
14
29254530
10
26461882
6
28226980
7
49815502
8
98376014
1
62660624
2
105459164
2
1984549
6
10390919
1
91185422
10
87364316
8
132321917
4
41749443
8
139114773
11
5346249
6
27647843
7
116151921
21
31972506
8
65549360
10
135030554
2
1928480
10
118138962
12
132102188
1
248366399
8
114435951
2
1417164
13
112711380
5
152981133
8
72872845
4
147561203
16
5293539
7
157933750
6
29943464
2
119418938
1
229706215
6
10391237
14
82292196
10
132461281
5
140787623
12
59657344
8
65528567
1
221050491
11
107067568
5
84126213
6
27649120
11
6049230
8
65525631
19
52452447
2
2321788
11
88911467
5
150326174
11
5295849
10
130844884
6
10393778
1
152797107
16
1088479
18
70535389
5
166491296
7
126746802
4
111550830
5
166988043

151 more elements

A method for detecting a cell or tissue derived from an endometrial cancer patient compatible to preservation therapy, the method comprising:

detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cancer cell or tissue containing the cell;
and
detecting a cell or tissue derived from the endometrial cancer patient compatible to preservation therapy, on the basis of the detected DNA methylation level,
wherein the target CpG site is at least one CpG site selected from the group consisting of CpG sites located at or near the chromosomal positions listed in Table A.
TABLE A
CpG site
Chromosome
Chromosomal
Chromosome
Chromosomal
Chromosome
Chromosomal
No.
position
No.
position
No.
position
10
106400259
13
112759355
10
18583838
8
56852290
7
35301188
12
61961255
14
60973823
14
29254530
10
26461882
6
28226980
7
49815502
8
98376014
1
62660624
2
105459164
2
1984549
6
10390919
1
91185422
10
87364316
8
132321917
4
41749443
8
139114773
11
5346249
6
27647843
7
116151921
21
31972506
8
65549360
10
135030554
2
1928480
10
118138962
12
132102188
1
248366399
8
114435951
2
1417164
13
112711380
5
152981133
8
72872845
4
147561203
16
5293539
7
157933750
6
29943464
2
119418938
1
229706215
6
10391237
14
82292196
10
132461281
5
140787623
12
59657344
8
65528567
1
221050491
11
107067568
5
84126213
6
27649120
11
6049230
8
65525631
19
52452447
2
2321788
11
88911467
5
150326174
11
5295849
10
130844884
6
10393778
1
152797107
16
1088479
18
70535389
5
166491296
7
126746802
4
111550830
5
166988043

151 more elements

A method for determining malignant transformation risk of endometrium, the method comprising:

detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell or tissue containing the cell;
and
determining malignant transformation risk in the endometrium, on the basis of the detected DNA methylation level,
wherein the target CpG site is at least one CpG site selected from the group consisting of CpG sites located at or near the chromosomal positions listed in Table A.
TABLE A
CpG site
Chromosome
Chromosomal
Chromosome
Chromosomal
Chromosome
Chromosomal
No.
position
No.
position
No.
position
10
106400259
13
112759355
10
18583838
8
56852290
7
35301188
12
61961255
14
60973823
14
29254530
10
26461882
6
28226980
7
49815502
8
98376014
1
62660624
2
105459164
2
1984549
6
10390919
1
91185422
10
87364316
8
132321917
4
41749443
8
139114773
11
5346249
6
27647843
7
116151921
21
31972506
8
65549360
10
135030554
2
1928480
10
118138962
12
132102188
1
248366399
8
114435951
2
1417164
13
112711380
5
152981133
8
72872845
4
147561203
16
5293539
7
157933750
6
29943464
2
119418938
1
229706215
6
10391237
14
82292196
10
132461281
5
140787623
12
59657344
8
65528567
1
221050491
11
107067568
5
84126213
6
27649120
11
6049230
8
65525631
19
52452447
2
2321788
11
88911467
5
150326174
11
5295849
10
130844884
6
10393778
1
152797107
16
1088479
18
70535389
5
166491296
7
126746802
4
111550830
5
166988043

151 more elements

A primer or a probe for use in determining prognosis of endometrial cancer, determining an endometrial cancer patient compatible to preservation therapy, or determining risk of endometrial cancer,

wherein the primer or the probe has at least 12 base long, and is hybridizable with a target CpG site which has been treated with bisulfite, and
the target CpG site is at least one CpG site selected from the group consisting of CpG sites located at or near the chromosomal positions listed in Table A.
TABLE A
CpG site
Chromosome
Chromosomal
Chromosome
Chromosomal
Chromosome
Chromosomal
No.
position
No.
position
No.
position
10
106400259
13
112759355
10
18583838
8
56852290
7
35301188
12
61961255
14
60973823
14
29254530
10
26461882
6
28226980
7
49815502
8
98376014
1
62660624
2
105459164
2
1984549
6
10390919
1
91185422
10
87364316
8
132321917
4
41749443
8
139114773
11
5346249
6
27647843
7
116151921
21
31972506
8
65549360
10
135030554
2
1928480
10
118138962
12
132102188
1
248366399
8
114435951
2
1417164
13
112711380
5
152981133
8
72872845
4
147561203
16
5293539
7
157933750
6
29943464
2
119418938
1
229706215
6
10391237
14
82292196
10
132461281
5
140787623
12
59657344
8
65528567
1
221050491
11
107067568
5
84126213
6
27649120
11
6049230
8
65525631
19
52452447
2
2321788
11
88911467
5
150326174
11
5295849
10
130844884
6
10393778
1
152797107
16
1088479
18
70535389
5
166491296
7
126746802
4
111550830
5
166988043

149 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/298,863Filed 5 Dec 2019
Priority: JP 2018-2282765 Dec 2018
Published: 3 Feb 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12Q 2500/00
Analytical methods involving nucleic acids
C12Q 2600/106
Oligonucleotides characterized by their use: pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/118
Oligonucleotides characterized by their use: prognosis of disease development

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key